DCT

0:26-cv-61712

GlaxoSmithKline IP Development Ltd v. Transpire Bio Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 0:26-cv-61712, S.D. Fla., 06/16/2026
  • Venue Allegations: Venue is alleged to be proper as Defendant Transpire is a Florida corporation that resides in the judicial district.
  • Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) for a generic version of the asthma and COPD treatment TRELEGY ELLIPTA constitutes an act of infringement of four patents covering both the drug compositions and the dry-powder inhaler device technology.
  • Technical Context: The lawsuit involves drug-device combination products in the respiratory medicine market, specifically dry-powder inhalers used to deliver multiple active pharmaceutical ingredients for treating asthma and Chronic Obstructive Pulmonary Disease (COPD).
  • Key Procedural History: This action was filed under the Hatch-Waxman Act following Defendant's notice letter regarding its ANDA submission, triggering an automatic 30-month stay on FDA approval of the generic product. The asserted patents are listed in the FDA's Orange Book as covering Plaintiff's TRELEGY ELLIPTA product. The complaint also references prior patent litigation between the parties involving different ANDA filings.

Case Timeline

Date Event
2005-12-12 Earliest Priority Date for '281 Patent
2005-07-28 Earliest Priority Date for '242 Patent
2009-12-01 Earliest Priority Date for '726 Patent and '986 Patent
2013-09-17 '281 Patent Issued
2014-06-10 '242 Patent Issued
2017-09-05 '726 Patent Issued
2017-09-18 FDA approves TRELEGY ELLIPTA 100/62.5/25 mcg for COPD treatment
2020-09-09 FDA approves TRELEGY ELLIPTA 100/62.5/25 mcg and 200/62.5/25 mcg for asthma treatment
2025-08-26 '986 Patent Issued
2025-11-21 Counterclaim filed in prior litigation (Case 0:25-cv-61939)
2026-03-06 Separate action filed against Transpire (Case 0:26-cv-60696)
2026-05-07 Defendant's Notice Letter sent to Plaintiff
2026-05-11 Counterclaim filed in prior litigation (Case 0:26-cv-60696)
2026-06-16 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,534,281 - "Manifold For Use In Medicament Dispenser"

Issued September 17, 2013 ('281 Patent)

The Invention Explained

  • Problem Addressed: The patent describes the challenge of ensuring efficient and uniform delivery of dry powder medicaments, particularly for combination therapies using multiple blister packs, where achieving a high Fine Particle Fraction (FPF) is critical for therapeutic efficacy '281 Patent, col. 1:16-28
  • The Patented Solution: The invention is a manifold for a dry powder inhaler that uses a specific airflow geometry to improve drug delivery. It splits incoming air into two paths: a primary path that flows through the open drug blister to entrain the powder, and a secondary "bleed" path that bypasses the blister and injects "bleed airflow" directly into the chamber to "disruptively impact the airflow that transports the entrained medicament powder" '281 Patent, abstract '281 Patent, col. 6:5-24 This turbulence is intended to de-agglomerate the drug particles.
  • Technical Importance: This manifold design provided a mechanical means to improve the aerosolization of combination dry powder therapies, potentially increasing the amount of respirable drug delivered to the lungs from a simple, breath-actuated device.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶46
  • The essential elements of claim 1 include:
    • A manifold body for a medicament dispenser.
    • A "chimney" with a single inlet and plural exits to direct airflow.
    • A "chamber" with plural inlets and a single exit.
    • Plural pairings of chimney exits and chamber inlets, each associated with a different open blister pocket.
    • A side-by-side arrangement of each chimney exit and chamber inlet to direct airflow through the blister pockets to entrain the powder.
    • "one or more bleed holes" between the chimney and the chamber, allowing "bleed airflow" to be directed into the chamber to "disruptively impact the airflow that transports the entrained medicament powder."
  • The complaint reserves the right to assert other claims Compl. ¶46

U.S. Patent No. 8,746,242 - "Medicament Dispenser"

Issued June 10, 2014 ('242 Patent)

The Invention Explained

  • Problem Addressed: The patent addresses the risk of accidental dose actuation in multi-dose inhalers that use a movable mouthpiece cover. Users may wish to open the cover for inspection or cleaning without dispensing a dose, which could lead to wasted medication and incorrect patient dosing '242 Patent, col. 1:44-53
  • The Patented Solution: The invention is a dispenser with a cover that moves sequentially through three positions: 1) covered, 2) part-uncovered, and 3) uncovered. The dispensing mechanism is coupled to the cover such that moving from the first to the second position does not actuate a dose, but further movement from the second to the third position does result in actuation '242 Patent, abstract '242 Patent, col. 2:22-34
  • Technical Importance: This design introduces a safety feature into the user interface of a dry powder inhaler, preventing inadvertent dose wastage while still allowing the convenience of an integrated mouthpiece cover.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶63
  • The essential elements of claim 1 include:
    • A medicament dispenser for use with a carrier holding multiple distinct medicament portions.
    • An actuable dispensing mechanism.
    • A mouthpiece.
    • A movable cover for the mouthpiece with a three-position sequential movement (covered, part-uncovered, uncovered).
    • The cover is coupled to the dispensing mechanism such that movement from position 1 to 2 does not cause actuation, but movement from position 2 to 3 does cause actuation.
  • The complaint reserves the right to assert other claims Compl. ¶63

U.S. Patent No. 9,750,726 - "Combinations Of A Muscarinic Receptor Antagonist And A Beta-2 Adrenoreceptor Agonist"

Issued September 5, 2017 ('726 Patent)

  • Technology Synopsis: This patent claims specific pharmaceutical combination products. It covers the combination of umeclidinium (a muscarinic receptor antagonist) and vilanterol (a beta-2 adrenoreceptor agonist), and a triple-therapy combination that also includes fluticasone furoate, formulated as a dry powder for once-daily, simultaneous administration for treating respiratory diseases like asthma and COPD '726 Patent, abstract '726 Patent, col. 5:25-32
  • Asserted Claims: At least claims 1 and 8 Compl. ¶79
  • Accused Features: The accused generic product is alleged to be a pharmaceutical combination product containing umeclidinium bromide, vilanterol trifenatate, and fluticasone furoate, in the form of a dry powder for once-daily, simultaneous administration, which allegedly infringes the claimed compositions Compl. ¶¶83-90

U.S. Patent No. 12,396,986 - "Combinations Of A Muscarinic Receptor Antagonist And A B-2 Adrenoreceptor Agonist"

Issued August 26, 2025 ('986 Patent)

  • Technology Synopsis: This patent, related to the '726 patent, claims pharmaceutical combination products comprising specific chemical compounds. The claims cover a combination of "Compound (I)" (a genus including umeclidinium) and "Compound (II)" (vilanterol), formulated as a dry powder for once-daily, simultaneous administration '986 Patent, abstract The complaint provides a chemical structure diagram of 'Compound (I)' to visually define the umeclidinium compound at issue Compl. p. 24
  • Asserted Claims: At least claims 1, 2, 3, 5, and 14 Compl. ¶99
  • Accused Features: The accused generic product is alleged to contain the specific chemical compounds, dosages, and administration forms (dry powder for simultaneous, once-daily use) recited in the claims, including umeclidinium bromide as "Compound (I)" and vilanterol trifenatate as "Compound (II)" Compl. ¶¶103-107 Compl. ¶112 Compl. ¶122

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendant Transpire's proposed generic version of TRELEGY ELLIPTA 200/62.5/25 mcg, which is the subject of ANDA No. 221261 filed with the FDA Compl. ¶3

Functionality and Market Context

The product is a dry powder formulation for oral inhalation containing three active ingredients: 200 mcg fluticasone furoate, 62.5 mcg umeclidinium bromide, and 25 mcg vilanterol trifenatate Compl. ¶39 It is intended for the maintenance treatment of asthma and is designed to be bioequivalent to GSK's branded TRELEGY ELLIPTA product Compl. ¶40 The complaint alleges the product will be used in an inhaler device that constitutes a medicament dispenser Compl. ¶48 Compl. ¶65 The filing of the ANDA signifies Defendant's intent to market this product as a lower-cost generic alternative upon receiving FDA approval, which would directly compete with Plaintiff's product (Compl. ¶¶3; Compl. ¶14).

IV. Analysis of Infringement Allegations

'281 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of each of plural blister packs... Defendant's proposed generic product allegedly has a manifold for use with a dispenser device delivering powder from plural blister packs. ¶50 col. 1:6-15
said body defining a chimney having only a single chimney inlet and plural chimney exits... The manifold of the accused product is alleged to have a body defining a chimney with a single inlet and plural exits. ¶52 col. 3:32-35
the body further defining a chamber having plural chamber inlets and a chamber exit... The manifold of the accused product is alleged to have a body defining a chamber with plural inlets and an exit. ¶53 col. 3:36-37
wherein the chimney exits and chamber inlets are arranged to form plural pairings... each said pairing in use associated with an open blister pocket of a different one of said plural blister packs; The accused product's manifold is alleged to have chimney exits and chamber inlets arranged in plural pairings, each associated with a different blister pack. ¶54 col. 3:62-67
wherein the chimney exit and chamber inlet of the plural pairings lie side-by-side each other... to entrain said medicament powder... and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder. The accused product's manifold is alleged to have side-by-side chimney exits and chamber inlets and one or more bleed holes between the chimney and chamber that direct bleed airflow to disruptively impact the airflow transporting the powder. ¶55 col. 6:5-10

'242 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions... Defendant's proposed generic product allegedly comprises a medicament dispenser for use with a carrier holding multiple distinct medicaments. ¶67 col. 2:6-9
(a) a dispensing mechanism actuable for dispensing the distinct medicament portions... The accused dispenser is alleged to have a dispensing mechanism that can be actuated to dispense the medicaments. ¶68 col. 2:10-12
(b) a mouthpiece; and The accused dispenser is alleged to have a mouthpiece. ¶69 col. 2:13
(c) a cover for said mouthpiece, said cover being movably mounted to the dispenser for sequential movement from a first position... to a second position... to a third position... The accused dispenser is alleged to have a movable cover for the mouthpiece that moves sequentially through first (covered), second (part-uncovered), and third (uncovered) positions. ¶70 col. 2:14-21
wherein said cover is adapted to couple with said dispensing mechanism such that movement of the cover from the first position to the second position does not result in actuation... but any further movement of the cover from the second position to the third position results in actuation... The accused dispenser's cover is alleged to be coupled to the dispensing mechanism such that actuation only occurs on movement from the second to the third position, not from the first to the second. ¶71 col. 2:22-28

Identified Points of Contention

  • Structural and Functional Equivalence (Device Patents): For both the '281 and '242 patents, the central dispute will likely involve a detailed comparison of the accused generic inhaler's physical structure and mechanism of action against the specific claim limitations.
    • For the '281 Patent, a key question is whether the accused device's manifold contains "bleed holes" that perform the claimed function of "disruptively impact[ing] the airflow." This raises a technical question of whether any air passages in the accused device meet this specific functional requirement, or if they serve a different purpose.
    • For the '242 Patent, a point of contention may be the definition of the "second position, in which said mouthpiece is part-uncovered." The infringement analysis will turn on whether the accused device's cover operates with the claimed three-position, selective-actuation sequence, raising questions about how the intermediate state of the accused device compares to the claimed "part-uncovered" state.
  • Claim Scope (Composition Patents): For the '726 and '986 patents, which claim specific chemical combinations and formulations, the analysis will focus on whether the defendant's ANDA product literally meets each limitation. Potential points of contention could arise over the interpretation of terms like "about" with respect to dosages (e.g., "about 62.5 mcg/dose") and whether the specific salts used in the generic product fall within the claimed scope (e.g., "umeclidinium bromide" as an embodiment of "Compound (I)").

V. Key Claim Terms for Construction

'281 Patent, Claim 1

  • The Term: "to disruptively impact the airflow"
  • Context and Importance: This term is functional and defines the required purpose of the "bleed airflow." The infringement analysis will depend on whether the airflow in the accused device has a "disruptive" effect as claimed, a term that is not explicitly defined by a simple structure. Practitioners may focus on this term because its interpretation will determine whether any secondary air channel in the accused device, regardless of its primary purpose, can be said to meet this functional limitation.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The specification suggests that the bleed airflow itself, by creating "regions of differential force," promotes the desired powder break up, which could support an argument that any introduction of a secondary airstream that causes turbulence is "disruptive" '281 Patent, col. 6:15-24
    • Evidence for a Narrower Interpretation: The patent states the purpose of the disruptive impact is to "promote the break up (e.g. to de-aggregate or de-agglomerate) of the entrained medicament powder" '281 Patent, col. 6:15-18 A defendant may argue this requires a specific, measurable effect on powder de-agglomeration, not just general turbulence.

'242 Patent, Claim 1

  • The Term: "a second position, in which said mouthpiece is part-uncovered"
  • Context and Importance: This term defines the crucial intermediate state of the cover that acts as a gate for actuation. The case may turn on whether the accused device has a stable, intermediate position that can be considered "part-uncovered" but not yet actuating, or if its opening mechanism is a continuous motion without such a distinct, non-actuating intermediate state.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language itself does not specify a degree of "part-uncovered," which could support an argument that any position between fully closed and fully open qualifies, as long as it does not trigger actuation.
    • Evidence for a Narrower Interpretation: The figures, such as Figures 3b and 4b, depict a specific state where the mouthpiece is partially, but not fully, revealed '242 Patent, Fig. 3b '242 Patent, Fig. 4b A party could argue these embodiments define the required scope of "part-uncovered" as a distinct, stable position where the device can rest before the final, actuating movement.

VI. Other Allegations

Indirect Infringement

For all four asserted patents, the complaint alleges both induced and contributory infringement. The allegations are based on Defendant's alleged knowledge of the patents and its intention for the proposed generic product and its labeling to be used in an infringing manner. The complaint asserts that the product is "especially made or adapted for use in infringing" the patents and is "not suitable for any substantial noninfringing use" Compl. ¶57 Compl. ¶73 Compl. ¶93 Compl. ¶129

Willful Infringement

The complaint alleges willful infringement for all four patents. The basis for this allegation is the claim that Defendant had "actual and constructive knowledge" of the patents prior to filing its ANDA and was aware that the filing itself constituted an act of infringement Compl. ¶56 Compl. ¶60 Compl. ¶72 Compl. ¶76 Compl. ¶92 Compl. ¶96 Compl. ¶128 Compl. ¶132

VII. Analyst's Conclusion: Key Questions for the Case

This case presents a classic Hatch-Waxman dispute involving both drug-device and composition-of-matter patents. The outcome will likely depend on the court's resolution of the following central questions:

  1. A core issue will be one of structural and functional infringement: For the device patents ('281 and '242), does the defendant's proposed generic inhaler, which must be bioequivalent to the branded product, also incorporate the specific mechanical features recited in the claims? This includes the '281 patent's "bleed holes" that "disruptively impact" airflow and the '242 patent's three-position, selective-actuation cover mechanism.
  2. A second key question will be one of literal claim scope: For the composition patents ('726 and '986), does the defendant's formulation-including the precise chemical compounds, their salt forms, specific dosages, and delivery as a dry powder for simultaneous administration-fall squarely within the literal boundaries of the asserted claims?
  3. A final evidentiary question will be one of knowledge and intent: Should direct or indirect infringement be found, the court will need to assess the evidence presented regarding the defendant's alleged pre-suit knowledge of the patents to determine whether the infringement was willful, which could expose the defendant to enhanced damages.
Loading Complaint